Elizabeth O'Farrell gets 13,700 SpyGlass Pharma (SGP) options

Rhea-AI Filing Summary

SpyGlass Pharma director Elizabeth G. O'Farrell received a stock option grant covering 13,700 shares of common stock on February 5, 2026. The option has an exercise price of $16 per share, expires on February 5, 2036, and was awarded at no cost to her.

The option will vest 100% on the earlier of one year after the grant date or immediately before the next annual meeting of stockholders, provided she continues as an Outside Director. Following this grant, she beneficially owns options for 13,700 shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider O'Farrell Elizabeth G.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	13,700	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 13,700 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Farrell Elizabeth G.

(Last) (First) (Middle)

C/O SPYGLASS PHARMA, INC.

27061 ALISO CREEK RD., SUITE 100

(Street)

ALISO VIEJO CA 92656

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SpyGlass Pharma, Inc. [ SGP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$16	02/05/2026		A		13,700		(1)	02/05/2036	Common Stock	13,700	$0	13,700	D

Explanation of Responses:

1. Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2026 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the date immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean February 5, 2026.

	/s/ Brian Aukshunas, as Attorney-in-Fact	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did SpyGlass Pharma (SGP) report for Elizabeth G. O'Farrell?

SpyGlass Pharma reported a grant of stock options to director Elizabeth G. O'Farrell. She acquired options to purchase 13,700 shares of common stock, reflecting director compensation rather than an open-market purchase of existing shares.

How many SpyGlass Pharma (SGP) shares are covered by the new option grant?

The new stock option grant covers 13,700 shares of SpyGlass Pharma common stock. This entire amount is reflected as beneficially owned in derivative form following the transaction, according to the Form 4 disclosure for director Elizabeth G. O'Farrell.

What is the exercise price and term of Elizabeth O'Farrell's SpyGlass Pharma options?

The stock options have an exercise price of $16 per share and expire on February 5, 2036. This gives the director a long-dated right to buy SpyGlass Pharma common stock at that fixed price if the options vest.

When do Elizabeth O'Farrell's SpyGlass Pharma (SGP) options vest?

The options vest 100% on the earlier of one year after the February 5, 2026 grant date or immediately before the next annual stockholder meeting. Vesting requires that she continue serving as an Outside Director through the applicable vesting date.

Did Elizabeth O'Farrell pay anything for the SpyGlass Pharma option grant?

The Form 4 shows a price of $0 for the derivative security, indicating she did not pay to receive the option grant. Her economic cost arises only if she later exercises the options at the $16 per share exercise price.